Faes Farma, S.a. · BME:FAE

Faes Farma — FY2023 Earnings Presentation

19 slides from Faes Farma's earnings presentation, December 2023

  1. Slide 1: Caring for tomorrow, today – Business results 2023

    Caring for tomorrow, today Business results 2023

  2. Slide 2: Index

    1// Revisión 3 // Overview financiera Financial review Index 2// Business evolution 2023 FAES FARMA/Caring for tomorrow, today 2

  3. Slide 3: Highlights

    Overview 2023 Highlights Business International markets, both direct sales and licensing, continue to be the growth drivers. Strong evolution of bilastine (+10%) and calcifediol (+11%), both reaching record annual revenues. Performance 11th consecutive year of growth in revenues and profits. Financi

  4. Slide 4: R&D&i

    R&D&i Investigation advancing New molecule research advances in regulatory preclinical phases, possibility of clinical trials in 2025-2026 Innovation advancing Two key innovation projects have entered the clinical pase: mesalazine 1500 an mesalazine granules. Calcifediol weekly dose Dossier submitte

  5. Slide 5: Key figures

    Overview 2023 Key figures +2,5% +1,2% Total Income EBITDA* 473 M€ 122 M€ Income top 3 +8% +1,3% EBIT** molecules 183 M€ 103 M€ Total +6% +2,5% International Net profit income 263 M€ 92 M€ *Operating profit before depreciation and amortization **Operating profit FAES FARMA/Caring for tomorrow, today

  6. Slide 6: Index

    1// Revisión 3 // Overview financiera Financial review Index 2// Business evolution 2023 FAES FARMA/Caring for tomorrow, today 6

  7. Slide 7: Growth driven by the top molecules

    Business evolution 2023 Growth driven by the top molecules Total income by product line Pharma business 89% / Animal Nutrition and health 11% Animal nutrition 2023 M€ and health Pharma top 3 Total income by portfolio line 2023 2022 % 11% molecules Pharma 420,4 402,5 4% 39% Pharma top 3 molecules 182

  8. Slide 8: Sales evolution top 3 molecules

    Business evolution 2023 Sales evolution top 3 molecules Growth in all major markets to a new annual revenue record: • Growth in Spain and Portugal driven by new launches. BILASTINE +10% • Bilastine license sales continues to grow despite the end of patent in Europe. 120,4 M€ • Good organic growth in

  9. Slide 9: Growth driven by international markets, accounting for 56% of total revenues

    Business evolution 2023 Growth driven by international markets, accounting for 56% of total revenues Total income by business area and geography M€ Total income by business area 2023 2022 % Animal 2023 Pharma 420,4 402,5 4% nutrition and Pharma Spain 161,8 160,2 1% health Pharma Spain Pharma Interna

  10. Slide 10: Spain Pharma – 8% growth without the effect of the discontinuation of Ristaben&Ristfor

    Business evolution 2023 Spain Pharma – 8% growth without the effect of the discontinuation of Ristaben&Ristfor Highlights 2023 Total income M€ 2023 2022 %var Slightly more positive evolution than Spain Pharma 161,8 160,2 1% expected. Prescription 103,4 105,3 -2% Prescription: Notable performance of

  11. Slide 11: International Pharma (without licenses) – Latam and MEA key growth drivers

    Business evolution 2023 International Pharma (without licenses) – Latam and MEA key growth drivers (+8%) Total income Highlights 2023 M€ 2023 2022 %var International (without licences) 159,1 146,8 8% Latam subsidiaries: Subsidiaries LATAM 85,6 79,2 8% Central America Dominican 26,6 25,6 Mexico (+47%

  12. Slide 12: Licenses – good overall performance of the different licenses

    Business evolution 2023 Licenses – good overall performance of the different licenses Total income Highlights 2023 M€ 2023 2022 %var Licenses 99,6 95,5 4% Bilastine: Bilastine 83,9 80,1 5% • Strong growth in sell out in markets such as Turkey (+172%) and Canada (+30%) • In Japan, the growth in volum

  13. Slide 13: Animal Nutrition and Health – 2023 impacted by the market challenges in Iberia

    Business evolution 2023 Animal Nutrition and Health–2023 impacted by the market challenges in Iberia Total income Highlights 2023 M€ 2023 2022 %var Animal nutrition and health 52,7 59,3 -11% General reduction of the market in Iberia mainly due to emerging diseases which Ingaso Farm 29,8 34,3 reduced

  14. Slide 14: Index

    1// Revisión 3 // Overview financiera Financial review Index 2// Business evolution 2023 FAES FARMA/Caring for tomorrow, today 14

  15. Slide 15: Income statement

    Financial review Income statement Thousand € 2023 % of sales 2022 % of sales %change Ordinary income (sales) 451.168 438.754 2,8% Other operating income 21.926 4,9% 22.965 5,2% -4,5% Tota Income 473.094 104,9% 461.719 105,2% 2,5% Gross margin Cost of sales -154.050 -34,1% -156.739 -35,7% -1,7% impro

  16. Slide 16: Cash Flow. Positive financial position despite record capital investment level

    Financial review Cash Flow. Positive financial position despite record capital investment level Thousand € 2023 Profit before tax 102.852 Depreciation and amortisation 19.398 Change in working capital -15.380 Solid financial position (34 M€) Other adjustments -5.901 despite high out flow from invest

  17. Slide 17: Results 2023. Internal EBITDA targets met despite slower revenue growth

    Results 2023. Internal EBITDA targets met despite slower revenue growth FORECASTS REAL Total income Growth ~4,0% vs. 2022 Growth 2,5% vs. 2022 97% compliance, lower than budgeted revenue growth due to the performance of animal nutrition, Mexico and Colombia vs expectatons. 2022: 462M€ 2023E: 475M€ -

  18. Slide 18: Disclaimer

    Disclaimer This presentation has been prepared and published by Faes Farma Group and is presented for information purposes only. This presentation is not a prospectus and does not constitute an offer or recommendation to make an investment. This presentation does not constitute a commitment to subsc

  19. Slide 19: Faes Farma – Caring for tomorrow, today

    Ch FAES FARMA Caring for tomorrow, today

Faes Farma — FY2023 Earnings Presentation on 6ix